Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrizio Armeni

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Clinical Therapeutics|June 28, 2020
Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health ServicePatrizio Armeni, Ludovica Borsoi, Giulia Fornaro, et al.
Clinical Therapeutics|October 4, 2022
Use of Resource Modeling to Quantify the Organizational Impact of Subcutaneous Formulations for the Treatment of Oncologic Patients: The Case of Daratumumab in Multiple MyelomaCarlo Federici, Carla Rognoni, Francesco Costa, et al.
Leukemia & Lymphoma|July 9, 2024
Elicitation of societal preferences for chronic lymphocytic leukemia's treatments: a discrete choice experimentLudovica Borsoi, Francesco Costa, Carlo Milano, et al.
Hematology (Amsterdam, Netherlands)|November 29, 2024
Optimizing treatment sequencing in multiple myeloma: a novel model to predict survival outcomesMaria Teresa Petrucci, Sara Bringhen, Cristina Entrala Cerezo, et al.
Clinical Therapeutics|May 2, 2020
Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health ServicePatrizio Armeni, Ludovica Borsoi, Giulia Fornaro, et al.
BMC Anesthesiology|November 6, 2025
The economic burden of anesthetic-related adverse events: a systematic review and empirical analysisPatrizio Armeni, Francesco Costa, Giulia Fornaro, et al.
Expert Opinion on Biological Therapy|April 25, 2022
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasisPaolo Gisondi, Davide Geat, Patrizio Armeni, et al.
Journal of Pharmaceutical Policy and Practice|May 17, 2023
Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian caseAlice Tarantola, Monica Hildegard Otto, Patrizio Armeni, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|October 14, 2023
Collecting Physicians' Preferences on Medical Devices: Are We Doing It Right? Evidence from Italian Orthopedists Using 2 Different Stated Preference MethodsPatrizio Armeni, Michela Meregaglia, Ludovica Borsoi, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|August 17, 2023
Cost-effectiveness analysis of pressure-controlled intermittent coronary sinus occlusion in elective percutaneous coronary interventionCarla Rognoni, Gaia Segantin, Roberto Scarsini, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Clinical Therapeutics|June 28, 2020
Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health ServicePatrizio Armeni, Ludovica Borsoi, Giulia Fornaro, et al.
Clinical Therapeutics|October 4, 2022
Use of Resource Modeling to Quantify the Organizational Impact of Subcutaneous Formulations for the Treatment of Oncologic Patients: The Case of Daratumumab in Multiple MyelomaCarlo Federici, Carla Rognoni, Francesco Costa, et al.
Leukemia & Lymphoma|July 9, 2024
Elicitation of societal preferences for chronic lymphocytic leukemia's treatments: a discrete choice experimentLudovica Borsoi, Francesco Costa, Carlo Milano, et al.
Hematology (Amsterdam, Netherlands)|November 29, 2024
Optimizing treatment sequencing in multiple myeloma: a novel model to predict survival outcomesMaria Teresa Petrucci, Sara Bringhen, Cristina Entrala Cerezo, et al.
Clinical Therapeutics|May 2, 2020
Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health ServicePatrizio Armeni, Ludovica Borsoi, Giulia Fornaro, et al.
BMC Anesthesiology|November 6, 2025
The economic burden of anesthetic-related adverse events: a systematic review and empirical analysisPatrizio Armeni, Francesco Costa, Giulia Fornaro, et al.
Expert Opinion on Biological Therapy|April 25, 2022
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasisPaolo Gisondi, Davide Geat, Patrizio Armeni, et al.
Journal of Pharmaceutical Policy and Practice|May 17, 2023
Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian caseAlice Tarantola, Monica Hildegard Otto, Patrizio Armeni, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|October 14, 2023
Collecting Physicians' Preferences on Medical Devices: Are We Doing It Right? Evidence from Italian Orthopedists Using 2 Different Stated Preference MethodsPatrizio Armeni, Michela Meregaglia, Ludovica Borsoi, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|August 17, 2023
Cost-effectiveness analysis of pressure-controlled intermittent coronary sinus occlusion in elective percutaneous coronary interventionCarla Rognoni, Gaia Segantin, Roberto Scarsini, et al.
Pageof 5